Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02706392 · ClinicalTrials.gov registry record · Phase 1
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02706392 is a Phase 1 study that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 21 participants.
The verdict
NCT02706392, a Phase 1 study, was terminated before completion, sponsored by Fred Hutchinson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of genetically modified T-cell therapy in treating patients with receptor tyrosine kinase-like orphan receptor 1 positive (ROR1+) chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), stage IV non-small cell lung cancer (NSCLC), or triple negative breast cancer (TNBC) that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Genetically modified therapies, such as ROR1 specific chimeric antigen receptor (CAR) T-cells, are taken from a patient's blood, modified in the laboratory so they specifically may kill cancer cells with a protein called ROR1 on their surfaces, and safely given back to the patient after conventional therapy. The "genetically modified" T-cells have genes added in the laboratory to make them recognize ROR1.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL ROR1 CAR-specific Autologous T-Lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-03-16 |
| Est. Completion | 2021-09-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02706392
The ClinicalTrials.gov registry entry for NCT02706392 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02706392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02706392 about?
NCT02706392 is a clinical study titled "Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies". This phase I trial studies the side effects and best dose of genetically modified T-cell therapy in treating patients with receptor tyrosine kinase-like orphan receptor 1 positive (ROR1+) chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), stage IV non...
What is the current status of trial NCT02706392?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2016-03-16. Estimated completion is 2021-09-28.
What interventions are being tested in trial NCT02706392?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), ROR1 CAR-specific Autologous T-Lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT02706392?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.